The present mini review evaluates assessment and comorbidity of glaucoma and depression with the possibilities of treatment options. Web of science was searched for relevant articles using search terms "glaucoma", "depression", "glaucoma and depression", "quality of life and glaucoma". The additional relevant papers were added from the bibliography of selected papers. All types of articles were included, no time period was defined. We have reviewed 11 studies regarding the comorbidities of glaucoma and depression. The number of participants in all studies ranged from 86 to 6760. Formats of scale in one study was clinician rated, others were self-reported scales. Two studies of the above mentioned studies explored specific types of glaucoma. In the three studies out of 11 there was no significant evidence of elevated depressive symptoms associated with glaucoma. In the six studies the prevalence of depression was significant among glaucoma patients. One study provided suboptimal assessments of depression in glaucoma patients. The other one showed the presence of glaucoma significantly associated with depression after adjustment for the demographic factor. Most of the studies used one scale, while two of them used two scales. The reviewed studies did not analyze the therapy options of included patients. The results presented in this review indicate that glaucoma is accompanied by depression in the majority of analyzed studies. The comorbidity of glaucoma and depression should be the subject of further research on both, self-reflecting and clinician-rated scales, taking into account subjective experience of patients and physicians. The therapy options should be taken into account in future researches focusing on the multidisciplinary approach including novel possibilities of treating both diseases respectively.

Purpose: To analyze the retinal and choriocapillaris changes in diabetic patients with no or with early signs of diabetic retinopathy using high-definition (HD) angio optical coherence tomography angiography (OCTA) software and spectral-domain (SD) OCT. Methods: A total of 112 eyes (54 eyes from 27 diabetic patients and 58 eyes from 29 control subjects) were included in this retrospective cross-sectional study of healthy and diabetic adults. Retinal microvascular changes were assessed by using HD-OCTA software to calculate vascular density (VD) and foveal avascular zone (FAZ). SD-OCT was used to assess retinal thickness and volume in parafovea as well as ganglion cell complex (GCC) parameters. Results: The VD-whole image was significantly higher in the healthy control group (MW z = 1109.5, p = 0.012; t = 2.611, p = 0.010). Also, VD-parafovea was significantly higher in the healthy subjects (MW z = 1053.5, p = 0.004; t = 3.207, p = 0.002). GCC focal loss volume (FLV) was significantly decreased in diabetic patients (p = 0.051). Non-flow FAZ did not show a statistically significant difference between groups, although the FAZ was larger in the diabetic patients. Conclusions: Diabetic patients with no or early signs of diabetic retinopathy have decreased VD compared to healthy individuals. They also present retinal changes at the GCC that are correlated with initial neurodegeneration. HD-OCTA and SD-OCT can detect vascular changes and structural signs of retinal neurodegeneration before clinically apparent diabetic retinopathy. Potentially, these methods may offer new biomarkers for monitoring disease progression and visual prognosis.

The aim of the study was to determine the role of blepharospasm as a protective factor for the anterior segment of the eye by comparing the degree of blepharospasm and changes of the anterior segment structures. The study included sixty...

Background: Glaucoma is a group of eye conditions that damage the optic nerve, and it can be interconnected with psychoneurotic disorders due to the psychological and emotional stress that comes with such a chronic condition. The aim of this study was to examine the characteristics of the occurrence of anxiety, depression and open-angle glaucoma (OAG) in glaucoma patients from December 2023 to December 2024. Methods: This cross-sectional study was conducted on 200 patients with three different stages of OAG. Multiple questionnaires were used to determine the influence of different OAG stages on the severity of anxiety and depression. Results: While predicting the anxiety expression, in a multivariate logistic regression (stepwise method), there was a significant model in predicting the expression of anxiety: female gender (Odds ratio (OR) = 3.03), age of 66 and over (OR = 3.4) and the feeling of being under stress (OR = 7.07). In the prediction of a higher severity of depression, predictors are age 66 and older (OR = 2.03) and feeling stressed (OR = 9.47). Conclusions: While glaucoma and psychoneurotic disorders affect different systems in the body, the psychological toll of living with glaucoma can lead to exacerbation of glaucoma.

Background: Depression and anxiety are highly prevalent among medical students and may adversely affect academic functioning and professional development. Early identification of these symptoms and their associated factors is therefore essential. Religiosity has been suggested as a potential modifier of mental health outcomes, although existing evidence remains inconsistent. This study aimed to assess symptoms of depression and anxiety, levels of religiosity, and their associations among medical students. Methods: This cross-sectional study was conducted among medical students at the University of Osijek, Croatia, from 29 September to 5 October 2025. Anxiety symptoms were assessed using the Generalized Anxiety Disorder-7 (GAD-7) scale, depressive symptoms using the Patient Health Questionnaire-9 (PHQ-9), and religiosity using the Duke University Religion Index (DUREL). Results: A total of 260 students (197 females, 63 males) completed the survey. At least mild depressive and anxiety symptoms were reported by 54.2% and 58.1%, respectively; 9.2% had moderately severe or severe depression, and 25% reported moderate to severe anxiety. Suicidal or self-harm ideation in the past two weeks occurred in 12.8%. Female students had higher median depression (p = 0.01) and anxiety scores (p = 0.005) than male students; however, these differences did not remain statistically significant after Bonferroni correction. Religiosity was not associated with PHQ-9 or GAD-7 scores after correction; however, categorical analyses indicated that students with moderate to high religiosity more frequently reported moderate to severe depressive symptoms (p = 0.037). Conclusions: The high prevalence of depression, anxiety, and suicidal ideation underscores the need for continuous mental health screening, early identification of risk factors, and implementation of preventive programs among the student population, particularly medical students as future healthcare professionals.

Cervical dystonia (CD), blepharospasm (BSP), and idiopathic hemifacial spasm (HFS) are focal hyperkinetic movement disorders with distinct underlying mechanisms. While CD and BSP involve central network dysfunctions within the basal ganglia-thalamo-cortical and cerebellar circuits, HFS primarily results from peripheral facial nerve hyperexcitability. Still, people living with all three conditions often struggle with mood issues like depression and anxiety, which can originate from both the burden of illness and changes in brain biology. We studied 61 patients (CD, n = 30; BSP, n = 9; HFS, n = 22) and assessed depression and anxiety before and three weeks after botulinum neurotoxin type A (BoNT-A) therapy, considering injection site and dose. BoNT-A significantly reduced depressive and anxiety symptoms across all groups, regardless of disease type, dose, or glabellar injection. These psychiatric improvements were not associated with the degree of motor symptom reduction, suggesting a partially independent mechanism of mood modulation. Our findings indicate that BoNT-A’s mood benefits may extend beyond local motor effects, possibly involving broader sensorimotor-limbic interactions. These results highlight the therapeutic potential of BoNT-A for addressing non-motor symptoms in both dystonic and non-dystonic hyperkinetic disorders. Future studies employing imaging and neurophysiological methods are necessary to explain the neural pathways underlying these effects.